Opthea Limited's (ASX:OPT): Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The AU$872m market-cap company announced a latest loss of -AU$20.9m on 30 June 2019 for its most recent financial year result. The most pressing concern for investors is OPT’s path to profitability – when will it breakeven? Below I will provide a high-level summary of the industry analysts’ expectations for OPT.
OPT is bordering on breakeven, according to the 3 Biotechs analysts. They anticipate the company to incur a final loss in 2020, before generating positive profits of AU$130m in 2021. So, OPT is predicted to breakeven approximately a couple of months from now! In order to meet this breakeven date, I calculated the rate at which OPT must grow year-on-year. It turns out an average annual growth rate of 15% is expected, which seems relatively fair. Should the business grow at a slower rate, it will become profitable at a later date than expected.
I’m not going to go through company-specific developments for OPT given that this is a high-level summary, but, bear in mind that by and large a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means a double-digit growth rate is not unusual, especially if the company is currently in an investment period.
Before I wrap up, there’s one aspect worth mentioning. OPT currently has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. This means that OPT has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
There are too many aspects of OPT to cover in one brief article, but the key fundamentals for the company can all be found in one place – OPT’s company page on Simply Wall St. I’ve also compiled a list of important factors you should look at:
- Historical Track Record: What has OPT's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Opthea’s board and the CEO’s back ground.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.